GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Aclaris Therapeutics Inc (FRA:8AT) » Definitions » Forward Dividend Yield %

Aclaris Therapeutics (FRA:8AT) Forward Dividend Yield % : 0.00% (As of Jun. 01, 2024)


View and export this data going back to 2017. Start your Free Trial

What is Aclaris Therapeutics Forward Dividend Yield %?

As of today (2024-06-01), the Forward Annual Dividend Yield of Aclaris Therapeutics is 0.00%.

As of today (2024-06-01), the Trailing Annual Dividend Yield of Aclaris Therapeutics is 0.00%.

FRA:8AT's Forward Dividend Yield % is not ranked *
in the Medical Diagnostics & Research industry.
Industry Median: 1.51
* Ranked among companies with meaningful Forward Dividend Yield % only.

Aclaris Therapeutics's Dividends per Share for the three months ended in Mar. 2024 was €0.00.

The growth rate is calculated with least square regression.

For more information regarding to dividend, please check our Dividend Page.


Competitive Comparison of Aclaris Therapeutics's Forward Dividend Yield %

For the Diagnostics & Research subindustry, Aclaris Therapeutics's Forward Dividend Yield %, along with its competitors' market caps and Forward Dividend Yield % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aclaris Therapeutics's Forward Dividend Yield % Distribution in the Medical Diagnostics & Research Industry

For the Medical Diagnostics & Research industry and Healthcare sector, Aclaris Therapeutics's Forward Dividend Yield % distribution charts can be found below:

* The bar in red indicates where Aclaris Therapeutics's Forward Dividend Yield % falls into.



Aclaris Therapeutics Forward Dividend Yield % Calculation

Dividend Yield measures how much a company pays out in dividends each year relative to its share price.


Aclaris Therapeutics  (FRA:8AT) Forward Dividend Yield % Explanation

Over the long term, the return from dividends has been a significant contributor to the total returns produced by equity securities. Studies by Elroy Dimson, Paul Marsh, and Mike Staunton of Princeton University (2002) found that a market-oriented portfolio, which included reinvested dividends, would have generated nearly 85 times the wealth generated by the same portfolio relying solely on capital gains.

Dividends may also qualify a lower tax rate for investors.

In dividends investing, Payout Ratio and Dividend Growth Rate are the two most important variables for consideration. A lower payout ratio may indicate that the company has more room to increase its dividends.

You can find the stocks that owned most by Gurus here. Or you can check out Warren Buffett's highest dividend stocks here.


Aclaris Therapeutics Forward Dividend Yield % Related Terms

Thank you for viewing the detailed overview of Aclaris Therapeutics's Forward Dividend Yield % provided by GuruFocus.com. Please click on the following links to see related term pages.


Aclaris Therapeutics (FRA:8AT) Business Description

Traded in Other Exchanges
Address
640 Lee Road, Suite 200, Wayne, PA, USA, 19087
Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing innovative therapies to address significant unmet needs for immuno-inflammatory diseases. The contract research segment earns revenue from the provision of laboratory services. The majority of its revenue comes from the contract research segment, which provides laboratory services. Its drug candidates under development are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138 is an ITJ Inhibitor; and ATI-1777.

Aclaris Therapeutics (FRA:8AT) Headlines

No Headlines